Impact of risk stratification according to ALL-BFM 90 and ALL-BFM 95 risk criteria in non-HR patients of the 2 trials (univariate Cox regression analysis)
| . | N . | 6y-pEFS, % (SE) . | Risk ratio . | 95% confidence interval . | P (Wald) . |
|---|---|---|---|---|---|
| ALL-BFM 90 | |||||
| SR-90 | 635 | 85.4 (1.4) | 1 | ||
| MR-90 | 1285 | 81.7 (1.1) | 1.40 | 1.11-1.77 | .005 |
| SR-95 | 826 | 88.7 (1.1) | 1 | ||
| MR-95 | 1094 | 78.7 (1.3) | 1.99 | 1.59-2.49 | <.001 |
| ALL-BFM 95 | |||||
| SR-90 | 683 | 88.2 (1.3) | 1 | ||
| MR-90 | 1207 | 81.0 (1.1) | 1.66 | 1.29-2.12 | <.001 |
| SR-95 | 758 | 89.5 (1.1) | 1 | ||
| MR-95 | 1157 | 79.7 (1.2) | 2.05 | 1.60-2.63 | <.001 |
| . | N . | 6y-pEFS, % (SE) . | Risk ratio . | 95% confidence interval . | P (Wald) . |
|---|---|---|---|---|---|
| ALL-BFM 90 | |||||
| SR-90 | 635 | 85.4 (1.4) | 1 | ||
| MR-90 | 1285 | 81.7 (1.1) | 1.40 | 1.11-1.77 | .005 |
| SR-95 | 826 | 88.7 (1.1) | 1 | ||
| MR-95 | 1094 | 78.7 (1.3) | 1.99 | 1.59-2.49 | <.001 |
| ALL-BFM 95 | |||||
| SR-90 | 683 | 88.2 (1.3) | 1 | ||
| MR-90 | 1207 | 81.0 (1.1) | 1.66 | 1.29-2.12 | <.001 |
| SR-95 | 758 | 89.5 (1.1) | 1 | ||
| MR-95 | 1157 | 79.7 (1.2) | 2.05 | 1.60-2.63 | <.001 |